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Abstract 
 Introduction: Hyperglycemia and insulin resistance are common in 
critically ill patients, even if they have not previously had diabetes, and the 
risk of mortality or significant morbidity is high among those who are treated 
in the intensive care unit (ICU) for more than 5 days. 
Objective: To assess the effect of glucose management protocol on mortality 
and morbidity 
in a heterogeneous population of critically ill adult patients. 
Design: A randomized controlled trial. 
Setting: A 24-bed medical-surgical intensive care unit (ICU) for adult 
patients at King 
Hussein Medical Center, the Royal Medical Services. 
Methods: A total of 50 patients who were considered to need intensive care 
for at least three days, were randomly assigned into two groups. The 
intervention group subjects were to undergo a glucose control protocol with 
insulin infusion titrated to maintain blood glucose level in a target range of 
120-160 mg/dL; except septic patients, in whom the target was higher, 160- 
180 mg/dL. Patients in the second group (control group) were treated by a 
European Scientific Journal June 2016 edition vol.12, No.18  ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
185 
conventional approach with reduction of blood glucose level only if the level 
was markedly elevated (>200 mg/dL) to maintain blood glucose level in a 
target range of 180-200 mg/dL. 
Results: After adjustment for baseline characteristics the 2 groups of patients 
were well matched, for age, sex, prevalence of diabetes mellitus, HbA1c 
value and distribution of diagnoses; the only significant difference was in the 
percentage of cardiovascular dysfunction, which was higher in the 
intervention group (p=0.047). After institution of the protocol, the mean 
blood glucose levels differed significantly between the two treatment groups 
during the study period (143.70±12.78 mg/dL in the intervention group 
versus 175.56±14.07 mg/dL in the control group (p<0.001). And patients in 
the intervention group received a larger mean insulin dose 28.32 ±16.38 
units per day, vs. 14.60±12.26 in the control group (p=0.001). The difference 
in mortality between the two treatment groups was not significant at 28 days 
(p=0.370) and at 60 days (p=0.555). No significant increase in hypoglycemia 
episodes was reported in our blood glucose level target.  
Conclusion: The glucose management protocol resulted in significantly 
improved glycemic control and was not associated with increased rate of 
death or hypoglycemia.  
 
Keywords: Diabetes, glucose control, insulin, intervention, randomized 
controlled trial 
 
Introduction  
Stress induced hyperglycemia in critically ill patients 
 Hyperglycemia determined by a high serum glucose level above the 
normal parameters and it is a frequent, almost universal transient, stress-
related finding. It occurs in the majority of patients admitted to the ICU, 
even those who did not previously suffer from diabetes. At the time of 
admission, it is associated with an increased morbidity and mortality in 
critically ill patients (Block et al., 2006). Critically ill patients are 
particularly prone to hyperglycemia because of the complex metabolic and 
hormonal changes associated with the stress response imposed by any type 
of acute illness or injury leading to what is called diabetes of injury (Marik 
and Raghavan, 2004). 
 
The concept of stress-induced hyperglycemia 
 The concept of stress-induced hyperglycemia, typically defined as 
blood glucose (BG) concentrations >200 mg/dL, has been described for 
almost 150 years. Since there was no evidence of a causal relationship, the 
stress-induced hyperglycemia was only treated with exogenous insulin when 
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it exceeded 12 mmol/L (220 mg/dL). In patients with known diabetes, even 
higher levels were often tolerated (Mesotten  and Berghe , 2003). 
 Moderate hyperglycemia was often viewed as a buffer against 
hypoglycemia-induced brain damage and beneficial adaptive response to 
life-threatening illness. It was thought to ensure adequate supply of glucose 
to the brain, to erythrocytes, and to injured tissues through an activation of 
the hypothalamic-pituitary-adrenal axis to provide substrates for vital organ 
function from endogenous stores (Mizock, 1995). 
 This notion was recently challenged, and the overall increase in 
glucose turnover to be not beneficial. In 2001, however, the critical care 
community was forced to reconsider this dogma, as a large randomized, 
controlled, clinical study “the Leuven study” showed that preventing even 
moderate hyperglycemia during critical illness substantially improved 
outcome (Berghe et al., 2001). 
 The fact that hyperglycemia persists despite abundantly released 
insulin was considered an argument in favor of tolerating moderately 
elevated blood glucose levels during critical illness. Overwhelming evidence 
in both surgical and medical ICU patients conclusively demonstrates that 
hyperglycemia is a marker of severity of illness and is also an independent 
determinant of bad outcome, and is associated with a number of life-
threatening complications and death. Indeed, if one considers hyperglycemia 
of injury as beneficial in promoting cellular glucose uptake in non–insulin-
dependent tissues, tolerating modest degrees of hyperglycemia is beneficial 
(Shaw et al., 2005; Nasraway, 2006). 
 Patients in the intensive care unit (ICU) are predisposed to elevated 
blood glucose levels because of common clinical interventions, such as the 
use of corticosteroids, vasopressors, glucose-containing intravenous fluids 
used for drug or fluid administration, enteral or parenteral nutrition, and 
dialysis (Krinsley et al., 2005). 
 
Mortality and high admission glucose 
 Kosiborod et al (2005) found a relation between high admission 
glucose and increased mortality in elderly patients hospitalized with acute 
myocardial infarction (Kosiborod et al., 2005). A retrospective study was 
conducted on all injured patients admitted to the surgical ICU for more than 
48 hours. Nonsurvivors had higher average glucose than survivors (p<0.03). 
In ICU the mortality rate for newly hyperglycemic patients approached one 
in three (Umpierrez et al., 2002). A retrospective analysis of a heterogeneous 
population of critically ill patients revealed that even a modest degree of 
hyperglycemia was associated with increased hospital mortality 
(Krinsley et al., 2003). 
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Controlling hyperglycemia in ICU patients 
 Although extensive research efforts during the last decade focused on 
strategies to prevent or reverse the potentially lethal multiple organ failure, 
only few of them revealed positive results. One of these strategies is blood 
glucose control with insulin (Berghe., 2004). Another way for controlling 
hyperglycemia is by controlling the exogenous nutritional inputs (Chase et 
al., 2006). 
 
Study objectives 
 The main objective of the current study is to assess the influence of 
the blood glucose level control on the morbidity and mortality of intensive 
care unit patients. 
 
Materials and methods 
Study design and setting 
 A randomized, controlled trial study was conducted to manage blood 
glucose, and adult medical and surgical ICU patients, who received treatment 
in the ICU for 3 or more consecutive days, at King Hussein Medical Center, 
the Royal Medical Services were involved. 
 
Study population 
 Population of this study included ICU patients received at King 
Hussein Medical Center, the Royal Medical Services. 
 
Study sample   
 A total of 50 patients were included in this study and assigned 
randomly into two groups: control group (N=25 patients) and intervention 
group (N=25 patient). 
 
Study procedure 
 The study was approved by the Local Research Ethics Committee in 
the Royal Medical Services. The standard for obtaining informed consent for 
participation in the study was in the form of written informed consent from 
the conscious and comprehending patient, prior to enrollment in the study; 
however some patients were severely ill and/or were receiving sedative 
medications as part of their treatment. For those who were not able to 
provide consent, an explanatory statement was provided to their legal 
surrogate. 
 To ensure patient safety, the target blood glucose concentrations were 
closely monitored, and the results were known to the clinical staff treating 
the patients. As patient safety is paramount, it was not possible to blind the 
clinical staff in the ICU to treatment allocation. Eligible patients were 
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enrolled into the study between 25th of June 2009 and 12th of October, 
2009; and each patient followed for sixty days for living status. 
 Adults, who were expected to require treatment in the medical and 
surgical ICU for 3 or more consecutive days, and within 24 hours after 
admission to an intensive care unit, were eligible for the study. 
 
 Inclusion criteria were if  
- Duration of required treatment in the ICU is 3 or more consecutive 
days after admission. 
- Patients who had an arterial line or central line in situ or the 
placement of the lines was imminent as part of routine ICU management. 
- Need for insulin therapy. 
- Informed consent was approved by the patient or his/her legal 
surrogate. 
 
Exclusion criteria were if: 
-  Age is less than 18 years. 
- Imminent death (cardiac standstill or brain death anticipated in less 
than 24 hours.  
- Patients were admitted to the ICU for treatment of diabetic 
ketoacidosis or for hyperosmolar state. 
- Patients who had previously suffered hypoglycemia without a 
documented full neurological recovery. 
- Patients who were considered at abnormally high risk of suffering 
hypoglycemia (e.g. known insulin secreting tumor or history of unexplained 
or recurrent hypoglycemia or fulminant hepatic failure). 
- Patients cannot provide prior informed consent and there is 
documented evidence that the patient has no legal surrogate and it appears 
unlikely that the patient will regain consciousness or sufficient ability to 
provide delayed informed consent. 
 
Data collection and follow up 
 Data collection included those variables necessary to define patient 
characteristics at baseline,  the incidence and severity of hyperglycemia and 
hypoglycemia, and documentation of deaths and other serious adverse events 
during follow up. The information that were sought from the entire patients 
demographic and clinical data were collected from patients files, daily 
medication sheets, verbally from patients surrogate and clinical laboratory 
data sheets. All information were collected in a data collection form eligible 
patients were randomly assigned into two groups: the intervention and the 
control. 
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Statistical Analysis 
 SAS, version 9.1, was used for statistical analysis. Clinical data were 
expressed as mean, median and as percentages. P values less than 0.05 were 
considered significant. For univariate analysis of end points Chi-square test 
or Fisher's exact test. Continuous variables were compared with the use of 
unpaired t-test, or Wilcoxon rank-sum test. The primary analysis for death at 
60 days and 28 days was performed with the use of an unadjusted chi-square 
test. 
 
Results  
Study participants 
Recruitment and follow up of study population 
 A total of 54 patients were recruited in this randomized controlled 
study. Two patients were excluded as they did not meet the inclusion criteria 
and the other two patients were lost to follow-up as they were from abroad, 
and their data were not analyzed. All remaining patients (n=50) were 
followed up for vital status, and they were randomly assigned to one of the 
two treatment groups: 25 to interventional glucose control (intervention 
group) and 25 to conventional glucose control (control group). 
 
The baseline characteristics of patients 
 It was found that the baseline characteristics were almost similar 
between the treatment groups as shown in Table 1, no significant differences 
were found in the mean (±SD) of age, the percentage of male patients, the 
mean (±SD) of weight, body-mass index and of HbA1c value between the 
two groups (p>0.05). No significant differences were detected in the 
percentage of operative admission between the intervention group (60%) and 
the control group (68%), and in the percentage of non- operative admissions 
between the two groups (p=0.55). 
 The percentage of patients admitted for operative causes was higher 
than those admitted for 
 medical causes in both groups. Difference in location before ICU 
admission was also not significant between the two groups (p= 0.178). 
 For organ dysfunction before randomization, no significant 
differences in respiratory, hepatic, coagulatory and renal dysfunctions were 
seen between the two groups (p>0.05). The only significant difference was in 
cardiovascular dysfunction, the percentage being higher in the intervention 
group (p= 0.047). 
 There were no significant differences in the percentages of patients 
on mechanical ventilation, those with history of diabetes mellitus type 2, 
previous treatment with insulin, previous treatment with systemic 
corticosteroids and smoking between the two groups (p>0.05). 
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 There was no history of diabetes mellitus type 1 in the two groups; all 
diabetic patients in the study were with history of diabetes mellitus type 2. 
Subgroup classifications at randomization including severe sepsis and trauma 
were not significantly different between the two groups (p>0.05). Blood 
glucose level before randomization in the control group was not significantly 
different from that in the intervention group (p>0.05). 
Table 1: Baseline characteristics of study patients 
Variable 
 
Intervention group 
 
Control group p-value 
Age – Yr, mean ±SD  58.28 ± 13.19 51.28 ± 15.7 0.94 
Male sex (%)  72% 60% 0.37 
Weight-kg, mean ±SD  81.76 ± 12.04 79.48± 9.57 0.46 
Body-mass index, mean ±SD  28.14 ± 2.71 28.16 ± 2.54 0.97 
Reason for ICU admission (%) 
• Operative 
• Nonoperative  
 
 
60 % 
40 % 
 
 
 
68 % 
32 % 
 
0.55 
 
Location before ICU admission 
(%) 
• Emergency department 
• Hospital floor 
• Another hospital 
• Operating room 
 
 
24% 
24% 
12% 
40% 
 
 
20% 
8% 
4% 
68% 
0.17 
Organ dysfunction (%) 
• Respiratory 
• Coagulatory 
• Cardiovascular 
• Hepatic 
• Renal 
 
88% 
44% 
60% 
24% 
28% 
 
84% 
68% 
32% 
16% 
20% 
 
0.68 
0.09 
0.04 
0.46 
0.50 
Mechanical ventilation (%)  92% 84% 0.135 
History of diabetes mellitus Type 
2 (%)  
60% 36% 0.093 
Previous treatment with insulin 
(%)  
32% 16% 0.185 
Previous treatment with systemic 
corticosteroids (%)  
8% 4% 0.551 
Subgroup classifications at 
randomization (%) 
• Severe sepsis 
• Trauma 
 
 
12% 
16% 
 
 
4% 
16% 
 
 
0.297 
1 
Smoking (%)  80% 64% 0.207 
HbA1c value, mean ±SD  6.36 ± 0.95 6.40 ± 0.81 0.86 
Blood glucose level before 
randomization mg/dL, mean ±SD  
259.44 ± 31.02 244.88 ± 29.19 0.09 
  
Glucose control and treatment effects 
 Patients enrolled in the intervention group were more likely than 
those in the control group to have received insulin (96% versus 72%, 
p=0.02), and they received a larger mean insulin dose 28.32 ±16.38 units per 
day, vs. 14.60± 12.26 in the control group (p=0.001). The median duration of 
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the insulin treatment was significantly different between the two groups 
(p=0.022). The time-weighted blood glucose level (with weighting based on 
the time difference between two consecutive measurements applied to the 
average of the two consecutive measurements) was computed for all the 
patients. The mean time-weighted blood glucose level was significantly 
lower in the intervention group than in the control group (143.70±12.78 
versus 175.56±14.07 mg/dL, p<0.001). The morning blood glucose level was 
also significantly lower in the intervention group than the level in the control 
group (138.56 ± 17.09 versus 174.04 ±16.69, p=0.001). Measures of 
glycemic control are shown in Table 2 and Figures 1 and 2. There was no 
significant difference in the percentage of patients who were treated with 
corticosteroids between the two groups (p=0.568). Mortality rates decreased, 
but not significantly in intervention group compared with control group as 
measured at (Table 2). 
Table 2: Blood glucose management and corticosteroid treatment 
Variable Intervention group Control group p-value 
    
Treated with insulin (%) 96% 72% 0.0206 
    
Insulin dose, units/day, 
28.32 ± 16.38 14.60 ± 12.26 0.0016 
mean ±SD    
    
Duration of insulin    
treatment days, median 3(0-31) 1(0-14) 0.022 
(minimum-maximum)    
    
Morning blood glucose, 
138.56 ± 17.09 174.04 ±16.69 0.001 
mg/dL, mean ±SD    
    
Mean time-weighted    
blood glucose level, 143.70 ± 12.78 175.56 ± 14.07 < 0.001 
mg/dL, mean ±SD    
    
Corticosteroid treatment, % 
48% 40% 0.568 
    
Mortality rate (%): 
At day 28 
At day 60 
28% 
32% 
40% 
40% 
0.370 
0.550 
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Figure 1: shows morning blood glucose levels over 14 days. Baseline data are the averages 
of the last blood glucose measurements obtained before randomization; day 1 data are the 
average levels from the time of randomization to the end of the day of randomization. 
 
 
Figure 2: The mean blood glucose levels of the two groups. Baseline data are the averages of 
blood glucose levels from the time of randomization to the end of the day of randomization 
for all patients in each group, then averages of daily blood glucose levels until ten days after 
randomization. Averages of the blood glucose level were significantly lower in the 
intervention group from those of the control group (p<0.001). 
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Discussion 
 The apparent contradiction between the adverse effects of 
hyperglycemia and increased administration of insulin provokes debate over 
the most appropriate target for glucose control. Controlling hyperglycemia 
without being too tight will result in the most benefit without increasing the 
risk for severe hypoglycemia (Bochicchio and Scalea, 2008). 
 A Joint Statement From the American Diabetes Association (2008) 
and American Association of Clinical Endocrinologists (2009) announced 
that it is important to consider that the severely ill patients in NICE-SUGAR 
trial -that reported an increase in mortality rate, and episodes of severe 
hypoglycemia with tight glycemic control- were treated intensively with 
intravenous insulin to very tight targets (target glucose level was 81–108 
mg/dL) compared to a control group whose glucose control was good 
(average glucose 144 mg/dL). This study should not lead to an abandonment 
of the concept of good glucose management in the hospital setting. 
 In light of the recently published NICE-SUGAR data, a systematic 
review and a new meta-analysis provide an updated estimate of the effect of 
such therapy on the risk of hypoglycemia and death. It has suggested that 
TGC protocols offer limited if any benefits in critically ill adults and 
revealed that these protocols resulted in a 3- to 5-fold increased risk of 
hypoglycemia. The meta-analysis examined 29 randomized controlled trials 
that met the predefined inclusion criteria with strict glycemic goals. Of the 
27 trials that examined mortality as an endpoint, 16 favored TGC and 11 
favored usual care, but the reductions in relative risk were statistically 
significant (95% confidence) in only 2 of the 16 favoring TGC and in none 
of the 11 favoring usual care. The only outcome for which TGC 
demonstrated a significantly reduced risk was the development of 
septicemia. This was seen in surgical intensive care patients but not in 
medical ICU which cannot exclude the possibility that some patients may 
benefit from intensive insulin therapy (Donald et al., 2009). 
 In our study a new range of glucose level was set to control 
hyperglycemia with an insulin infusion pump protocol used in the 
intervention group. A goal was to maintain blood glucose level within range 
of 120-160 mg/dL, for ICU patients in general in the intervention group, and 
the range of 160-180 mg/dL was set for septic patients, to prevent 
hypoglycemia, which is risky in this particular ICU population. While 
conventional treatment with an insulin infusion pump was maintained in the 
control group; that is to maintain blood glucose level less than 200 mg/dL for 
ICU patients in a target range of 180-200 mg/dL. 
 The above ranges for the intervention group were higher than the 
TGC protocol since negative outcomes reported in the NICE-SUGAR study 
increased the need to target safer blood glucose level at the same time 
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controlling hyperglycemia and preventing bad outcomes; a glucose levels in 
the mid-100s. Our goal was set before the recommendations by ADA and 
AACE were declared (Moghissi et al., 2009). 
 The management of blood glucose levels was standardized. Nearly all 
patients received their assigned treatment. The mean blood glucose levels 
differed significantly between the two treatment groups during the study 
period (143.70±12.78 versus 175.56±14.07 mg/dL, p<0.001). When insulin 
resistance decreased, lower insulin rates were able to maintain better blood 
glucose levels. 
 The difference in mortality remained not significant after adjustment 
for potential confounders at 28 days (p=0.370), and at 60 days (p=0.555), 
between two groups in our study. This finding agrees with the result of a 
meta-analysis stating that the different targets of intensive insulin therapy 
(glucose level [ 6.1 mmol/L versus [ 8.3 mmol/L) did not influence either 
mortality (Fahey et al., 2009). It was noticed by secondary subgroup analysis 
for the primary outcome that the percentage of death was significantly higher 
in medical ICU patients than surgical ICU patients (p= 0.015), indicating that 
surgical patients may benefit more from insulin treatment. As found in 
previous studies (Berghe et al., 2001, He et al., 2007) and a meta-analysis 
(Donald et al., 2009). 
 
Conclusion  
 Hyperglycemia develops commonly in the critically ill and impacts 
outcome in patients with diabetes but, even more so, in patients with stress-
induced hyperglycemia. Our trial showed that a blood glucose target of less 
than 160 mg per deciliter in general, and target of less than 180 for septic 
patients, did not significantly increase mortality more than a target of less 
than 200 mg /per deciliter among critically ill adult patients. Mortality rates 
were less in intervention group than in control group, but this was not 
statistically significant (p>0.05). 
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